Equities Analysts Set Expectations for MediWound Q2 Earnings

MediWound Ltd. (NASDAQ:MDWD - Free Report) - HC Wainwright raised their Q2 2025 earnings estimates for MediWound in a research note issued on Thursday, May 22nd. HC Wainwright analyst S. Ramakanth now anticipates that the biopharmaceutical company will post earnings per share of ($0.55) for the quarter, up from their prior forecast of ($0.66). HC Wainwright has a "Buy" rating and a $31.00 price target on the stock. The consensus estimate for MediWound's current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for MediWound's Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.63) EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.60) EPS, FY2027 earnings at ($1.34) EPS, FY2028 earnings at ($0.82) EPS and FY2029 earnings at $1.13 EPS.

A number of other research analysts have also recently issued reports on MDWD. Wall Street Zen raised shares of MediWound to a "sell" rating in a report on Friday, March 21st. Craig Hallum started coverage on shares of MediWound in a report on Friday, February 28th. They issued a "buy" rating and a $39.00 target price for the company. Finally, Alliance Global Partners started coverage on shares of MediWound in a report on Friday, May 2nd. They issued a "buy" rating and a $25.00 target price for the company. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $31.25.

MediWound Price Performance

MediWound stock traded up $0.95 during mid-day trading on Monday, reaching $21.32. The company had a trading volume of 108,381 shares, compared to its average volume of 91,543. MediWound has a 1 year low of $12.78 and a 1 year high of $24.00. The company has a market capitalization of $230.43 million, a P/E ratio of -7.35 and a beta of 0.30. The stock's 50-day simple moving average is $17.50 and its 200-day simple moving average is $17.65.

MediWound (NASDAQ:MDWD - Get Free Report) last announced its quarterly earnings data on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.58. The firm had revenue of $3.96 million during the quarter, compared to the consensus estimate of $5.20 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same quarter last year, the firm earned ($1.05) earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MDWD. GAMMA Investing LLC raised its position in shares of MediWound by 1,507.1% during the 1st quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 1,703 shares during the last quarter. R Squared Ltd acquired a new position in shares of MediWound during the 4th quarter worth approximately $32,000. Russell Investments Group Ltd. raised its position in shares of MediWound by 154.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 1,162 shares during the last quarter. Corebridge Financial Inc. raised its position in shares of MediWound by 17.1% during the 1st quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 665 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock worth $85,000 after purchasing an additional 999 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.